Finished the INHSU 2018, Jason Grebely highlights the themes that stood out in this edition of the congress, in an interview to News Farma. For the president of the International Network on Hepatitis in Substance Users (INHSU), in this congress “become very apparent that we need to learn from each other concerning to different models of care and thinking about how do we scale up programs to enhanced testing linkage to care and treat people who inject drugs”.
For Rui Tato Marinho, INHSU 2018 co-convenor, one of the most relevant aspects of INHSU 2018 was the opportunity to compare different models of care between different countries. Hosting this congress “has brought Portugal and its policies on stage” and “reinforced our international network”.
Feel the rhythm of the five days spent in Portugal, during the 7th International Symposium on Hepatitis Care in Substance Users (INHSU 2018). More than 700 participants from all around the world joined this event, attending dozens of sessions and hundreds of discussion opportunities to better diagnose, treat and manage the hepatitis C.
The Kirby Institute research, presented at the 7th International Symposium on Hepatitis Care in Substance Users (INHSU 2018) in Cascais, Portugal and published in The Lancet Gastroenterology and Hepatology, provides the strongest evidence-base to date to support the removal of restrictions to accessing hepatitis C therapy based on recent drug use. In an interview to News Farma, Behzad Hajarizadeh, from the Viral Hepatitis Clinical Research Program at the Kirby Institute and lead author on the study, explains the main conclusions of the investigation.